紫杉醇、卡铂联合化疗老年非小细胞肺癌时毒副作用及对策

来源 :大家健康(学术版) | 被引量 : 0次 | 上传用户:MHSLOVE
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:探讨老年NSCLC采用紫杉醇、卡铂联合化疗后的毒副作用及相应的措施。方法:选取在我院化疗的老年NSCLC患者64例,实施紫杉醇联合卡铂治疗,观察治疗后的毒性反应,并给予相应的措施。结果:64例患者化疗后均出现不同程度的骨髓抑制、胃肠道反应、肝肾功能损伤等不良反应,但通过粒细胞集落刺激因子(GCSF),5-羟色胺(5-HT)药物、受体拮抗剂、保肝等药物治疗,减少了化疗药物所致的毒性反应发生。结论:老年NSCLC患者实施紫杉醇联合卡铂治疗,治疗后出现的毒性反应,给予一定的预防及防治,有效的减轻了临床毒副作用,促进了化疗的顺利进行,疗效显著,值得临床推广。 Objective: To investigate the toxic side effects and corresponding measures of elderly patients with NSCLC treated with paclitaxel and carboplatin combined with chemotherapy. Methods: Totally 64 elderly patients with NSCLC undergoing chemotherapy in our hospital were enrolled in this study. Paclitaxel combined with carboplatin was given to treat the toxic reaction after treatment and the corresponding measures were given. RESULTS: Sixty-four patients had different degrees of myelosuppression, gastrointestinal reactions, liver and kidney dysfunction and other adverse reactions after chemotherapy. However, by the chemotherapy of granulocyte colony-stimulating factor (GCSF) and 5-hydroxytryptamine (5-HT) Body antagonists, liver and other drug treatment, reducing the toxicity of chemotherapy drugs occur. Conclusion: The elderly patients with NSCLC treated with paclitaxel combined with carboplatin, the toxicity after treatment, given some prevention and prevention, effectively reducing the clinical side effects and promote the smooth progress of chemotherapy, the effect is significant, worthy of clinical promotion.
其他文献
2019年5月初,《知识经济》曾对网红云商假借“360”和周鸿祎的名义,以“分红”和“股权”拉人头,涉嫌“多层次团队计酬”和“非法集资”的行为进行报道。近日,有报道称,从有
为了让个人所得税高效地发挥作用,《个人所得税专项附加扣除暂行办法》明确规定了子女教育、继续教育、大病医疗、普通住房贷款利息、住房租金、赡养老人支出6项个人所得税专
纳布啡是集阿片受体激动/拮抗效应为一身的新型阿片类药物,在临床主要适用于术后镇痛及外伤疼痛等各类疼痛治疗。因其可拮抗μ受体激动所引起的呼吸抑制、恶心、呕吐、瘙痒等